Emmaus Medical, Inc., headquartered in the United States, is a pioneering company in the biopharmaceutical industry, specialising in innovative treatments for rare diseases. Founded in 2008, Emmaus has made significant strides in developing therapies that address unmet medical needs, particularly in the field of sickle cell disease. The company’s flagship product, Endari, is a unique L-glutamine oral powder that has been clinically proven to reduce complications associated with sickle cell disease. This groundbreaking treatment has positioned Emmaus Medical as a leader in the market, with a commitment to improving patient outcomes and quality of life. With a strong operational presence across the US and expanding internationally, Emmaus Medical continues to achieve notable milestones, reinforcing its reputation as a trusted provider of specialised medical solutions.
We don't have data for Emmaus Medical, Inc., but we can show you information about their parent organization instead.
View parent company